A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

Science Translational Medicine

Volumn 7, Issue 302, 2015, Pages

  Saunders, Laura R ^a   Bankovich, Alexander J ^a   Anderson, Wade C ^a   Aujay, Monette A ^a   Bheddah, Sheila ^a   Black, KristenAnn ^a   Desai, Radhika ^a   Escarpe, Paul A ^a   Hampl, Johannes ^a   Laysang, Amy ^a   Liu, David ^a   Lopez Molina, Javier ^a   Milton, Milly ^a   Park, Albert ^a   Pysz, Marybeth A ^a   Shao, Hui ^a   Slingerland, Brian ^a   Torgov, Michael ^a,i   Williams, Samuel A ^a   Foord, Orit ^a   Howard, Philip ^b   Jassem, Jacek ^c   Badzio, Andrzej ^c   Czapiewski, Piotr ^c   Harpole, David H ^d   Dowlati, Afshin ^e   Massion, Pierre P ^f   Travis, William D ^g   Pietanza, M Catherine ^g,h   Poirier, J T ^g,h   Rudin, Charles M ^g   Stull, Robert A ^a   Dylla, Scott J ^a   more..

^a Stemcentrx   (United States)

^b ASTRAZENECA   (United Kingdom)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ ImaginAb Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE SC16LD6 5; ANTINEOPLASTIC AGENT; CELL PROTEIN; CISPLATIN; DELTA LIKE 3 PROTEIN; DNA DAMAGING DAMAGING PYRROLOBENZODIAZEPINE DIMER TOXIN; ETOPOSIDE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY LD6 5; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SC16; SHORT HAIRPIN RNA; TOXIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; DLL3 PROTEIN, HUMAN; MEMBRANE PROTEIN; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL SURFACE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS REACTION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG SYNTHESIS; EMBRYO; FEMALE; GENE EXPRESSION REGULATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERNALIZATION; LARGE CELL NEUROENDOCRINE CARCINOMA; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; OUTCOME ASSESSMENT; PATIENT DERIVED XENOGRAFT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY NEUROENDOCRINE TUMOR; SINGLE DRUG DOSE; SMALL CELL LUNG CANCER; TUMOR CELL; TUMOR INITIATING CELL; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; NEUROENDOCRINE TUMORS; NONOBESE DIABETIC MOUSE; SCID MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOCONJUGATES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; NEUROENDOCRINE TUMORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940403711     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac9459     Document Type: Article

References (53)

1. N. Rekhtman, Neuroendocrine tumors of the lung: An update. Arch. Pathol. Lab. Med. 134, 1628-1638 (2010).
2. W. D. Travis, Pathology and diagnosis of neuroendocrine tumors: Lung neuroendocrine. Thorac. Surg. Clin. 24, 257-266 (2014).
3. W. N. William Jr., B. S. Glisson, Novel strategies for the treatment of small-cell lung carcinoma. Nat. Rev. Clin. Oncol. 8, 611-619 (2011).
4. M. Joshi, A. Ayoola, C. P. Belani, Small-cell lung cancer: An update on targeted therapies. Adv. Exp. Med. Biol. 779, 385-404 (2013).
5. F. Eichhorn, H. Dienemann, T. Muley, A. Warth, H. Hoffmann, Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung. Ann. Thorac. Surg. 99, 983-989 (2015).
6. R. M. Merrill, D. E. Henson, M. Barnes, Conditional survival among patients with carcinoma of the lung. Chest 116, 697-703 (1999).
7. J. von Pawel, R. Jotte, D. R. Spigel, M. E. O'Brien, M. A. Socinski, J. Mezger, M. Steins, L. Bosquée, J. Bubis, K. Nackaerts, J. M. Trigo, P. Clingan, W. Schütte, P. Lorigan, M. Reck, M. Domine, F. A. Shepherd, S. Li, M. F. Renschler, Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J. Clin. Oncol. 32, 4012-4019 (2014).
8. A. van de Stolpe, On the origin and destination of cancer stem cells: A conceptual evaluation. Am. J. Cancer Res. 3, 107-116 (2013).
9. W. D. Travis, Advances in neuroendocrine lung tumors. Ann. Oncol. 21, vii65-vii71 (2010).
10. Clinical Lung Cancer Genome Project (CLCGP), Network Genomic Medicine (NGM), A genomics-based classification of human lung tumors. Sci. Transl. Med. 5, 209ra153 (2013).
11. C. M. Rudin, S. Durinck, E. W. Stawiski, J. T. Poirier, Z. Modrusan, D. S. Shames, E. A. Bergbower, Y. Guan, J. Shin, J. Guillory, C. S. Rivers, C. K. Foo, D. Bhatt, J. Stinson, F. Gnad, P. M. Haverty, R. Gentleman, S. Chaudhuri, V. Janakiraman, B. S. Jaiswal, C. Parikh, W. Yuan, Z. Zhang, H. Koeppen, T. D. Wu, H. M. Stern, R. L. Yauch, K. E. Huffman, D. D. Paskulin, P. B. Illei, M. Varella-Garcia, A. F. Gazdar, F. J. de Sauvage, R. Bourgon, J. D. Minna, M. V. Brock, S. Seshagiri, Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44, 1111-1116 (2012).
12. st century. Lab. Invest. 93, 970-982 (2013).
13. E. Rosfjord, J. Lucas, G. Li, H.-P. Gerber, Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology. Biochem. Pharmacol. 91, 135-143 (2014).
14. W. C. Anderson, M. B. Boyd, J. Aguilar, B. Pickell, A. Laysang, M. A. Pysz, S. Bheddah, J. Ramoth, B. C. Slingerland, S. J. Dylla, E. R. Rubio, Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates. PLOS One 10, e0125255 (2015).
15. J. T. Poirier, E. E. Gardner, N. Connis, A. L. Moreira, E. de Stanchina, C. L. Hann, C. M. Rudin, DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene 10.1038/onc.2015.38 (2015).
16. S. D. Reynolds, A. Giangreco, J. H. T. Power, B. R. Stripp, Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration. Am.J.Pathol. 156, 269-278 (2000).
17. K.-S. Park, M.-C. Liang, D. M. Raiser, R. Zamponi, R. R. Roach, S. J. Curtis, Z. Walton, B. E. Schaffer, C. M. Roake, A.-F. Zmoos, C. Kriegel, K.-K. Wong, J. Sage, C. F. Kim, Characterization of the cell of origin for small cell lung cancer. Cell Cycle 10, 2806-2815 (2011).
18. H. Song, E. Yao, C. Lin, R. Gacayan, M.-H. Chen, P.-T. Chuang, Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 109, 17531-17536 (2012).
19. K. D. Sutherland, N. Proost, I. Brouns, D. Adriaensen, J.-Y. Song, A. Berns, Cell of origin of small cell lung cancer: Inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 19, 754-764 (2011).
20. D. W. Ball, Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer. Cancer Lett. 204, 159-169 (2004).
21. M. Borges, R. I. Linnoila, H. J. K. van de Velde, H. Chen, B. D. Nelkin, M. Mabry, S. B. Baylin, D. W. Ball, An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 386, 852-855 (1997).
22. F. Guillemot, L.-C. Lo, J. E. Johnson, A. Auerbach, D. J. Anderson, A. L. Joyner, Mammalian achaete-scute homolog 1 is required for the early development of olfactory and autonomic neurons. Cell 75, 463-476 (1993).
23. Y. Li, R. I. Linnoila, Multidirectional differentiation of Achaete-Scute homologue-1-defined progenitors in lung development and injury repair. Am. J. Respir. Cell Mol. Biol. 47, 768-775 (2012).
24. T. Jiang, B. J. Collins, N. Jin, D. N. Watkins, M. V. Brock, W. Matsui, B. D. Nelkin, D. W. Ball, Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res. 69, 845-854 (2009).
25. M. Morimoto, R. Nishinakamura, Y. Saga, R. Kopan, Different assemblies of Notch receptors coordinate the distribution of the major bronchial Clara, ciliated and neuroendocrine cells. Development 139, 4365-4373 (2012).
26. P. Ntziachristos, J. S. Lim, J. Sage, I. Aifantis, From fly wings to targeted cancer therapies: A centennial for notch signaling. Cancer Cell 25, 318-334 (2014).
27. G. Chapman, D. B. Sparrow, E. Kremmer, S. L. Dunwoodie, Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum. Mol. Genet. 20, 905-916 (2011).
28. I. Geffers, K. Serth, G. Chapman, R. Jaekel, K. Schuster-Gossler, R. Cordes, D. B. Sparrow, E. Kremmer, S. L. Dunwoodie, T. Klein, A. Gossler, Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo. J. Cell Biol. 178, 465-476 (2007).
29. R. G. Fehon, P. J. Kooh, I. Rebay, C. L. Regan, T. Xu, M. A. Muskavitch, S. Artavanis-Tsakonas, Molecular interactions between the protein products of the neurogenic loci Notch and Delta, two EGF-homologous genes in Drosophila. Cell 61, 523-534 (1990).
30. S.L.Dunwoodie, D.Henrique, S.M.Harrison, R.S.Beddington, MouseDll3: A novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo. Development 124, 3065-3076 (1997).
31. E. Ladi, J. T. Nichols, W. Ge, A. Miyamoto, C. Yao, L.-T. Yang, J. Boulter, Y. E. Sun, C. Kintner, G. Weinmaster, The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J. Cell Biol. 170,983-992 (2005).
32. K. M. Loomes, S. A. Stevens, M. L. O'Brien, D. M. Gonzalez, M. J. Ryan, M. Segalov, N. J. Dormans, M. S. Mimoto, J. D. Gibson, W. Sewell, A. A. Schaffer, H.-D. Nah, E. F. Rappaport, S. C. Pratt, S. L. Dunwoodie, K. Kusumi, Dll3 and Notch1 genetic interactions model axial segmental and craniofacial malformations of human birth defects. Dev. Dyn. 236, 2943-2951 (2007).
33. I. Espinoza, L. Miele, Notch inhibitors for cancer treatment. Pharmacol. Ther. 139, 95-110 (2013).
34. M. Kunnimalaiyaan, H. Chen, Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist 12,535-542 (2007).
35. K. Serth, K. Schuster-Gossler, E. Kremmer, B. Hansen, B. Marohn-Köhn, A. Gossler, O-Fucosylation of DLL3 is required for its function during somitogenesis. PLOS One 10, e0123776 (2015).
36. R. M. Henke, D. M. Meredith, M. D. Borromeo, T. K. Savage, J. E. Johnson, Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube. Dev. Biol. 328, 529-540 (2009).
37. A. Augustyn, M. Borromeo, T. Wang, J. Fujimoto, C. Shao, P. D. Dospoy, V. Lee, C. Tan, J. P. Sullivan, J. E. Larsen, L. Girard, C. Behrens, I. I. Wistuba, Y. Xie, M. H. Cobb, A. F. Gazdar, J. E. Johnson, J. D. Minna, ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc. Natl. Acad. Sci. U.S.A. 111, 14788-14793 (2014).
38. H. Bouchard, C. Viskov, C. Garcia-Echeverria, Antibody-drug conjugates - a new wave of cancer drugs. Bioorg. Med. Chem. Lett. 24, 5357-5363 (2014).
39. N. Pedersen, S. Mortensen, S. B. Sørensen, M. W. Pedersen, K. Rieneck, L. F. Bovin, H. S. Poulsen, Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res. 63, 1943-1953 (2003).
40. J. T. Poirier, I. Dobromilskaya, W. F. Moriarty, C. D. Peacock, C. L. Hann, C. M. Rudin, Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J. Natl. Cancer Inst. 105, 1059-1065 (2013).
41. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin, S. Kim, C. J. Wilson, J. Lehár, G. V. Kryukov, D. Sonkin, A. Reddy, M. Liu, L. Murray, M. F. Berger, J. E. Monahan, P. Morais, J. Meltzer, A. Korejwa, J. Jané-Valbuena, F. A. Mapa, J. Thibault, E. Bric-Furlong, P. Raman, A. Shipway, I. H. Engels, J. Cheng, G. K. Yu, J. Yu, P. Aspesi Jr., M. de Silva, K. Jagtap, M. D. Jones, L. Wang, C. Hatton, E. Palescandolo, S. Gupta, S. Mahan, C. Sougnez, R. C. Onofrio, T. Liefeld, L. MacConaill, W. Winckler, M. Reich, N. Li, J. P. Mesirov, S. B. Gabriel, G. Getz, K. Ardlie, V. Chan, V. E. Myer, B. L. Weber, J. Porter, M. Warmuth, P. Finan, J. L. Harris, M. Meyerson, T. R. Golub, M. P. Morrissey, W. R. Sellers, R. Schlegel, L. A. Garraway, The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
42. F. Kosari, C. M. Ida, M.-C. Aubry, L. Yang, I. V. Kovtun, J. L. Klein, Y. Li, S. Erdogan, S. C. Tomaszek, S. J. Murphy, L. C. Bolette, C. P. Kolbert, P. Yang, D. A. Wigle, G. Vasmatzis, ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation. Oncogene 33,3776-3783 (2014).
43. M. Mairhofer, M. Steiner, U. Salzer, R. Prohaska, Stomatin-like protein-1 interacts with stomatin and is targeted to late endosomes. J. Biol. Chem. 284, 29218-29229 (2009).
44. K. Y. Choi, M. Swierczewska, S. Lee, X. Chen, Protease-activated drug development. Theranostics 2, 156-178 (2012).
45. G. M. Dubowchik, R. A. Firestone, L. Padilla, D. Willner, S. J. Hofstead, K. Mosure, J. O. Knipe, S. J. Lasch, P. A. Trail, Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigenspecific in vitro anticancer activity. Bioconjug. Chem. 13, 855-869 (2002).
46. I. Puzanov, W. Lee, A. P. Chen, M. W. Calcutt, D. L. Hachey, W. L. Vermeulen, V. J. Spanswick, C.-Y. Liao, J. A. Hartley, J. D. Berlin, M. L. Rothenberg, Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin. Cancer Res. 17, 3794-3802 (2011).
47. R. Pagliarini, W. Shao, W. R. Sellers, Oncogene addiction: Pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep. 16, 280-296 (2015).
48. H. Osada, Y. Tatematsu, Y. Yatabe, Y. Horio, T. Takahashi, ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res. 65, 10680-10685 (2005).
49. L. A. Garraway, W. R. Sellers, Lineage dependency and lineage-survival oncogenes in human cancer. Nat. Rev. Cancer 6, 593-602 (2006).
50. J. A. Hartley, V. J. Spanswick, N. Brooks, P. H. Clingen, P. J. McHugh, D. Hochhauser, R. B. Pedley, L. R. Kelland, M. C. Alley, R. Schultz, M. G. Hollingshead, K. M. Schweikart, J. E. Tomaszewski, E. A. Sausville, S. J. Gregson, P. W. Howard, D. E. Thurston, SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: Part 1: Cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res. 64, 6693-6699 (2004).
51. P. H. Clingen, I. U. De Silva, P. J. McHugh, F. J. Ghadessy, M. J. Tilby, D. E. Thurston, J. A. Hartley, The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. Nucleic Acids Res. 33, 3283-3291 (2005).
52. T. Ito, N. Udaka, T. Yazawa, K. Okudela, H. Hayashi, T. Sudo, F. Guillemot, R. Kageyama, H. Kitamura, Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development 127, 3913-3921 (2000).
53. B. M. Bolstad, R. A. Irizarry, M. Åstrand, T. P. Speed, A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193 (2003).